Analysis & Purity
Published August 3, 2026
One Name, Several Sequences: What "Uncharacterized" Actually Means
When the FDA's scientific reviewers recommended against adding seven peptides to the 503A compounding list in July 2026, the objection came in two parts. The first was familiar: not enough clinical data. The second was quieter, more technical, and — for anyone actually working with these compounds — more immediately useful. The agency's briefing materials noted that for these substances there are multiple forms, and in some cases multiple published amino acid sequences, under the same name.
Sit with that for a moment. It means that two vials, both honestly labelled with the same peptide name, may not contain the same molecule.
Why one name can cover more than one molecule
A peptide name is a label, not a specification. Several things can differ underneath it:
- Sequence variants in the literature. Some research peptides entered circulation through a small number of papers, and different papers occasionally report different sequences — an extra residue, a different terminus, a substitution. Once both versions are in print, both get synthesised.
- Terminal modifications. Free acid versus amidated C-terminus, free amine versus acetylated N-terminus. These are real chemical differences with real consequences for stability and behaviour in an assay, and a name rarely captures them.
- Counter-ion (salt form). Synthetic peptides usually arrive as a salt — commonly trifluoroacetate (TFA) or acetate. The peptide is the same; what comes with it is not. TFA in particular is a known variable in cell-based work.
- Net peptide content. Distinct from purity. A lot can be 99% pure by HPLC and still be a fraction of its stated mass in actual peptide, because the rest is counter-ion and residual water.
- Fragments and blends. Some familiar names describe a fragment of a larger protein or a mixture, not a single defined entity.
This is what "insufficiently characterised" means in a regulatory document. It is not an accusation of bad faith. It is a statement that the name alone does not pin down the substance.
Why it matters beyond regulation
The FDA reviewers' concern was about compounding. But the same property has a direct consequence for research: if the material is not standardised, results from different laboratories are hard to compare. Two groups can run the same experiment on the same named peptide, get different answers, and both be right about what was in their own vial.
That is the quiet reason why so much of the preclinical literature on these compounds is difficult to synthesise into a clear picture. Some of the variance is biology. Some of it is chemistry that was never controlled for.
What a Certificate of Analysis actually settles
A COA is the lot-specific laboratory report for the material in front of you. A complete one closes most of the gaps above:
| What it reports |
The question it answers |
| Mass spectrometry | Is the observed molecular mass the one this sequence predicts? This is the check that catches a different sequence sold under the same name. |
| HPLC purity | What proportion of the peptide material is the target peptide, rather than deletion sequences and synthesis by-products? |
| Counter-ion / salt form | TFA or acetate — a variable in cell-based assays. |
| Water content | Residual moisture, which affects both mass accounting and long-term stability. |
| Lot number and date | Whether this report describes your vial or a different production run. |
That last row is the one most often skipped. A COA for a different lot is a marketing document, not an analytical one.
What a COA does not settle
Being straight about the limits matters as much as listing the strengths:
- It says nothing about biological effect. Identity and purity are chemistry. Whether a compound does anything useful is a separate question answered by studies, not by a certificate.
- It says nothing about safety in humans or animals. A COA is not a safety assessment and never has been.
- It describes one lot at one moment. How the material was shipped and stored afterwards is outside its scope — which is why handling and storage remain the researcher's responsibility.
- It is only as good as the laboratory behind it. An independent third-party report and an in-house one are not equivalent evidence.
The practical takeaway
- Treat the name on the label as a starting point, not a specification.
- Ask for the COA for your lot, not a sample one.
- Check that the reported mass matches the sequence you intend to study.
- Note the salt form before designing anything cell-based.
- Read purity and net peptide content as two different numbers.
Research use only. This article is educational and concerns analytical chemistry and documentation. It is not medical advice and makes no safety, efficacy or treatment claim for humans or animals. All products sold by Universe Peptide are supplied strictly for laboratory research only, not for human or animal consumption, 21+. No dosing or administration guidance is provided.
Check the certificates before you buy
Universe Peptide publishes the third-party Certificate of Analysis for each compound on the site, so the report can be read before an order rather than after it:
View the published COAs →
Related reading
Sources & further reading
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — briefing documents and presentations. fda.gov
- Hawana JS. FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do. Mintz, 29 July 2026 — notes the multiple forms and multiple published amino acid sequences flagged in FDA's briefing materials. mintz.com
- Electronic Code of Federal Regulations. 21 CFR 216.23 — physical and chemical characterisation as an evaluation criterion. ecfr.gov